AR047076A1 - Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas - Google Patents
Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticasInfo
- Publication number
- AR047076A1 AR047076A1 ARP040104947A ARP040104947A AR047076A1 AR 047076 A1 AR047076 A1 AR 047076A1 AR P040104947 A ARP040104947 A AR P040104947A AR P040104947 A ARP040104947 A AR P040104947A AR 047076 A1 AR047076 A1 AR 047076A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- pharmaceutical compositions
- heterocyclyl
- aryl
- alkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 abstract 2
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 2
- 125000003107 substituted aryl group Chemical group 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 150000003921 pyrrolotriazines Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000005017 substituted alkenyl group Chemical group 0.000 abstract 1
- 125000004426 substituted alkynyl group Chemical group 0.000 abstract 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Los compuestos pertenecen a la categoría de pirrolotriazinas utilizados como agentes proliferativos. Composiciones farmacéuticas. Reivindicacion 1: Un compuesto de la formula (1) caracterizado porque R1 es cicloalquilo o cicloalquilo sustituido, arilo o arilo sustituido, heterociclilo o heterociclilo sustituido; R2 es arilo, arilo sustituido, heteroarilo o heteroarilo sustituido, heterociclilo o heterociclilo sustituido; R3 es H, alquilo o alquilo sustituido; X es un enlace directo, -NR3- o -O-; Y es un enlace directo, alquilo o alquilo sustituido, alquenilo o alquenilo sustituido, alquinilo o alquinilo sustituido; o una sal farmacéuticamente aceptable o estereoisomero del mismo, con la condicion de que R2 no es indazolilo o indazolilo sustituido.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53333503P | 2003-12-29 | 2003-12-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR047076A1 true AR047076A1 (es) | 2006-01-04 |
Family
ID=34748887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040104947A AR047076A1 (es) | 2003-12-29 | 2004-12-29 | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas |
Country Status (32)
| Country | Link |
|---|---|
| US (4) | US7141571B2 (es) |
| EP (2) | EP2058314A1 (es) |
| JP (1) | JP4740878B2 (es) |
| KR (1) | KR100839716B1 (es) |
| CN (1) | CN1922182B (es) |
| AR (1) | AR047076A1 (es) |
| AT (1) | ATE443706T1 (es) |
| AU (1) | AU2004312413C1 (es) |
| BR (1) | BRPI0418231A (es) |
| CA (1) | CA2552107C (es) |
| CL (1) | CL2009001492A1 (es) |
| CY (1) | CY1109662T1 (es) |
| DE (1) | DE602004023324D1 (es) |
| DK (1) | DK1699797T3 (es) |
| ES (1) | ES2331842T3 (es) |
| GE (1) | GEP20105081B (es) |
| HK (1) | HK1088332A1 (es) |
| HR (1) | HRP20090601T1 (es) |
| IL (1) | IL176450A0 (es) |
| MX (1) | MXPA06007038A (es) |
| MY (1) | MY145634A (es) |
| NO (1) | NO20062763L (es) |
| NZ (2) | NZ548070A (es) |
| PE (1) | PE20050679A1 (es) |
| PL (1) | PL1699797T3 (es) |
| PT (1) | PT1699797E (es) |
| RU (1) | RU2373209C2 (es) |
| SI (1) | SI1699797T1 (es) |
| TW (1) | TWI332840B (es) |
| UA (1) | UA89038C2 (es) |
| WO (1) | WO2005066176A1 (es) |
| ZA (1) | ZA200605160B (es) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6867300B2 (en) * | 2000-11-17 | 2005-03-15 | Bristol-Myers Squibb Company | Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors |
| PT1497019E (pt) * | 2002-04-23 | 2015-09-10 | Bristol Myers Squibb Co | Compostos de pirrolotriazina anilina úteis como inibidores de quinase |
| US20060014741A1 (en) * | 2003-12-12 | 2006-01-19 | Dimarco John D | Synthetic process, and crystalline forms of a pyrrolotriazine compound |
| MY145634A (en) * | 2003-12-29 | 2012-03-15 | Bristol Myers Squibb Co | Pyrrolotriazine compounds as kinase inhibitors |
| US7102002B2 (en) * | 2004-06-16 | 2006-09-05 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| US7173031B2 (en) * | 2004-06-28 | 2007-02-06 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| US7253167B2 (en) * | 2004-06-30 | 2007-08-07 | Bristol-Myers Squibb Company | Tricyclic-heteroaryl compounds useful as kinase inhibitors |
| TW200600513A (en) * | 2004-06-30 | 2006-01-01 | Bristol Myers Squibb Co | A method for preparing pyrrolotriazine compounds |
| US7504521B2 (en) * | 2004-08-05 | 2009-03-17 | Bristol-Myers Squibb Co. | Methods for the preparation of pyrrolotriazine compounds |
| TW200618803A (en) | 2004-08-12 | 2006-06-16 | Bristol Myers Squibb Co | Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors |
| TW200635927A (en) * | 2004-12-22 | 2006-10-16 | Bristol Myers Squibb Co | Synthetic process |
| US7358256B2 (en) | 2005-03-28 | 2008-04-15 | Bristol-Myers Squibb Company | ATP competitive kinase inhibitors |
| US20060235020A1 (en) * | 2005-04-18 | 2006-10-19 | Soojin Kim | Process for preparing salts of 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide and novel stable forms produced therein |
| MY150958A (en) | 2005-06-16 | 2014-03-31 | Astrazeneca Ab | Compounds for the treatment of multi-drug resistant bacterial infections |
| US8338594B2 (en) * | 2005-12-02 | 2012-12-25 | Bayer Healthcare Llc | Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase |
| US8063208B2 (en) * | 2006-02-16 | 2011-11-22 | Bristol-Myers Squibb Company | Crystalline forms of (3R,4R)-4-amino-1-[[4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol |
| WO2008057863A1 (en) * | 2006-11-01 | 2008-05-15 | Bristol-Myers Squibb Company | Therapeutic combination of a panher/vegfr2 kinase inhibitor and a platinum compound |
| ATE518946T1 (de) | 2007-02-08 | 2011-08-15 | Codexis Inc | Ketoreduktasen und anwendungen davon |
| US20090076034A1 (en) * | 2007-09-14 | 2009-03-19 | Protia, Llc | Deuterium-enriched bms-690514 |
| NZ585306A (en) * | 2007-12-19 | 2012-05-25 | Genentech Inc | 8-Anilinoimidazopyridines and their use as anti-cancer and/or anti-inflammatory agents |
| JP2010209058A (ja) * | 2008-09-29 | 2010-09-24 | Sumitomo Chemical Co Ltd | １−置換−トランス−４−（置換アミノ）ピペリジン−３−オールの製造方法 |
| EP2344504B1 (en) * | 2008-10-08 | 2014-06-04 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| ES2539620T3 (es) | 2008-12-19 | 2015-07-02 | Cephalon, Inc. | Pirrolotriazina como inhibidor de ALK y de JAK2 |
| CA2750047A1 (en) | 2009-01-21 | 2010-07-29 | Basilea Pharmaceutica Ag | Novel bicyclic antibiotics |
| WO2011013656A1 (ja) * | 2009-07-28 | 2011-02-03 | 第一三共株式会社 | ピロロ［２，３－ｄ］ピリミジン誘導体 |
| TWI510241B (zh) | 2010-02-18 | 2015-12-01 | Vtv Therapeutice Llc | 苯基－雜芳基衍生物及其使用方法 |
| JP5744021B2 (ja) | 2010-06-30 | 2015-07-01 | 富士フイルム株式会社 | 新規なニコチンアミド誘導体またはその塩 |
| CN102153558B (zh) * | 2011-02-23 | 2012-11-21 | 扬州永济医药新技术有限公司 | 多靶点抗肿瘤抑制剂2-氨吡咯-三嗪的衍生物及其合成方法 |
| DE102011119127A1 (de) * | 2011-11-22 | 2013-05-23 | Merck Patent Gmbh | 3-Cyanaryl-1H-pyrrolo[2.3-b]pyridin-Derivate |
| CN103450204B (zh) | 2012-05-31 | 2016-08-17 | 中国科学院上海药物研究所 | 吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途 |
| US9724352B2 (en) | 2012-05-31 | 2017-08-08 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Pyrrolo[2,1-F[1,2,4]triazine compounds, preparation methods and applications thereof |
| TW201414737A (zh) | 2012-07-13 | 2014-04-16 | 必治妥美雅史谷比公司 | 作爲激酶抑制劑之咪唑并三□甲腈 |
| CN105979950A (zh) | 2013-10-11 | 2016-09-28 | 百时美施贵宝公司 | 吡咯并三嗪激酶抑制剂 |
| AU2015205374B2 (en) * | 2014-01-13 | 2018-08-23 | Aurigene Oncology Limited | Bicyclic heterocyclyl derivatives as IRAK4 inhibitors |
| CN106537139B (zh) * | 2014-05-12 | 2019-04-16 | 奎斯特诊断投资公司 | 通过质谱法定量他莫昔芬及其代谢物 |
| AR112027A1 (es) | 2017-06-15 | 2019-09-11 | Biocryst Pharm Inc | Inhibidores de alk 2 quinasa que contienen imidazol |
| US12030897B2 (en) | 2018-05-08 | 2024-07-09 | Medshine Discovery Inc. | Pyrrolo[2,1-f][1,2,4]triazine derivatives serving as selective HER2 inhibitors and application thereof |
| WO2021088987A1 (zh) * | 2019-11-08 | 2021-05-14 | 南京明德新药研发有限公司 | 作为选择性her2抑制剂的盐型、晶型及其应用 |
| US20240132521A1 (en) * | 2022-08-22 | 2024-04-25 | Iambic Therapeutics, Inc. | Compounds and methods for modulating her2 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2163399A1 (en) | 1994-11-24 | 1996-05-25 | Katsuhiro Kawano | Triazine derivative, chymase activity inhibitor and nitric oxide production inhibitor |
| NZ333302A (en) | 1996-08-28 | 2000-08-25 | Pfizer | Substituted 6,5-hetero-bicyclic derivatives for the prevention or inhibition of a disorder that can be treated by antagonising corticotropin releasing factor |
| US6982265B1 (en) | 1999-05-21 | 2006-01-03 | Bristol Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
| EP1183033B1 (en) * | 1999-05-21 | 2006-03-01 | Bristol-Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
| AU6473600A (en) * | 1999-08-23 | 2001-03-19 | Shionogi & Co., Ltd. | Pyrrolotriazine derivatives having spla2-inhibitory activities |
| US6670357B2 (en) * | 2000-11-17 | 2003-12-30 | Bristol-Myers Squibb Company | Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors |
| US6867300B2 (en) * | 2000-11-17 | 2005-03-15 | Bristol-Myers Squibb Company | Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors |
| AU3276002A (en) | 2000-11-17 | 2002-05-27 | Bristol Myers Squibb Co | Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors |
| TW200300350A (en) * | 2001-11-14 | 2003-06-01 | Bristol Myers Squibb Co | C-5 modified indazolylpyrrolotriazines |
| AU2003221753A1 (en) | 2002-04-23 | 2003-11-10 | Bristol-Myers Squibb Company | Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors |
| PT1497019E (pt) | 2002-04-23 | 2015-09-10 | Bristol Myers Squibb Co | Compostos de pirrolotriazina anilina úteis como inibidores de quinase |
| US6894066B2 (en) | 2002-05-09 | 2005-05-17 | Bernard Charles Sherman | Magnesium salt of S-omeprazole |
| TW200407143A (en) | 2002-05-21 | 2004-05-16 | Bristol Myers Squibb Co | Pyrrolotriazinone compounds and their use to treat diseases |
| TWI272271B (en) | 2002-07-19 | 2007-02-01 | Bristol Myers Squibb Co | Process for preparing certain pyrrolotriazine compounds |
| TWI329112B (en) | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
| EP1543009A4 (en) | 2002-08-02 | 2007-08-08 | Bristol Myers Squibb Co | Pyrrolotriazine KINASE INHIBITORS |
| TW200420565A (en) * | 2002-12-13 | 2004-10-16 | Bristol Myers Squibb Co | C-6 modified indazolylpyrrolotriazines |
| US7102001B2 (en) | 2003-12-12 | 2006-09-05 | Bristol-Myers Squibb Company | Process for preparing pyrrolotriazine |
| MY145634A (en) * | 2003-12-29 | 2012-03-15 | Bristol Myers Squibb Co | Pyrrolotriazine compounds as kinase inhibitors |
| US7064203B2 (en) | 2003-12-29 | 2006-06-20 | Bristol Myers Squibb Company | Di-substituted pyrrolotriazine compounds |
| US7102002B2 (en) | 2004-06-16 | 2006-09-05 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| US7102003B2 (en) | 2004-07-01 | 2006-09-05 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds |
| US7151176B2 (en) * | 2004-10-21 | 2006-12-19 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds |
-
2004
- 2004-12-09 MY MYPI20045093A patent/MY145634A/en unknown
- 2004-12-22 US US11/019,901 patent/US7141571B2/en not_active Expired - Lifetime
- 2004-12-22 TW TW093140035A patent/TWI332840B/zh not_active IP Right Cessation
- 2004-12-23 MX MXPA06007038A patent/MXPA06007038A/es active IP Right Grant
- 2004-12-23 AU AU2004312413A patent/AU2004312413C1/en not_active Ceased
- 2004-12-23 KR KR1020067012936A patent/KR100839716B1/ko not_active IP Right Cessation
- 2004-12-23 UA UAA200608400A patent/UA89038C2/ru unknown
- 2004-12-23 SI SI200431286T patent/SI1699797T1/sl unknown
- 2004-12-23 CA CA2552107A patent/CA2552107C/en not_active Expired - Fee Related
- 2004-12-23 DE DE602004023324T patent/DE602004023324D1/de not_active Expired - Lifetime
- 2004-12-23 JP JP2006547328A patent/JP4740878B2/ja not_active Expired - Fee Related
- 2004-12-23 NZ NZ548070A patent/NZ548070A/en unknown
- 2004-12-23 PL PL04815269T patent/PL1699797T3/pl unknown
- 2004-12-23 EP EP09153694A patent/EP2058314A1/en not_active Withdrawn
- 2004-12-23 CN CN2004800421984A patent/CN1922182B/zh not_active Expired - Fee Related
- 2004-12-23 NZ NZ573544A patent/NZ573544A/en unknown
- 2004-12-23 WO PCT/US2004/043169 patent/WO2005066176A1/en active Application Filing
- 2004-12-23 RU RU2006127396/04A patent/RU2373209C2/ru not_active IP Right Cessation
- 2004-12-23 BR BRPI0418231-6A patent/BRPI0418231A/pt not_active IP Right Cessation
- 2004-12-23 ES ES04815269T patent/ES2331842T3/es not_active Expired - Lifetime
- 2004-12-23 PT PT04815269T patent/PT1699797E/pt unknown
- 2004-12-23 AT AT04815269T patent/ATE443706T1/de active
- 2004-12-23 GE GEAP20049544A patent/GEP20105081B/en unknown
- 2004-12-23 EP EP04815269A patent/EP1699797B1/en not_active Expired - Lifetime
- 2004-12-23 DK DK04815269T patent/DK1699797T3/da active
- 2004-12-29 AR ARP040104947A patent/AR047076A1/es not_active Application Discontinuation
-
2005
- 2005-01-03 PE PE2005000015A patent/PE20050679A1/es not_active Application Discontinuation
-
2006
- 2006-06-13 NO NO20062763A patent/NO20062763L/no not_active Application Discontinuation
- 2006-06-20 IL IL176450A patent/IL176450A0/en unknown
- 2006-06-22 ZA ZA200605160A patent/ZA200605160B/en unknown
- 2006-06-26 US US11/426,479 patent/US7297695B2/en not_active Expired - Lifetime
- 2006-09-19 HK HK06110373.0A patent/HK1088332A1/xx not_active IP Right Cessation
-
2008
- 2008-09-24 US US11/869,910 patent/US7846931B2/en not_active Expired - Lifetime
-
2009
- 2009-06-26 CL CL2009001492A patent/CL2009001492A1/es unknown
- 2009-11-09 HR HR20090601T patent/HRP20090601T1/hr unknown
- 2009-12-21 CY CY20091101326T patent/CY1109662T1/el unknown
-
2010
- 2010-10-25 US US12/911,299 patent/US20110039838A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
| PA8591701A1 (es) | Derivados de pirrolopirimidina | |
| AR046711A1 (es) | 5-7-diaminopirazolo[4,3d]pirimidinas como inhibidores de la pde-5,composiciones farmaceuticas que las contienen y usos en el tratamiento de hipertensiones | |
| AR045595A1 (es) | Composiciones utiles como inhibidores de proteinas quinasas | |
| PE20060570A1 (es) | Compuestos de quinazolina e isoquinolina piperidilo sustituidos como inhibidores de fosfodiesterasa pde-10 | |
| AR029216A1 (es) | Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento | |
| PE20090816A1 (es) | Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3 | |
| DE602004008098D1 (de) | Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren | |
| CR7548A (es) | Derivados de triazole como antagonistas del receptor de tachykinin | |
| AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
| AR058546A1 (es) | Derivados de 2- adamantilurea como inhibidores selectivos de 11 beta - hsd1 | |
| PE20030062A1 (es) | Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas | |
| EA200970461A1 (ru) | ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 3-ИЗОБУТИЛ-9,10-ДИМЕТОКСИ-1,3,4,6,7,11b-ГЕКСАГИДРО-2Н-ПИРИДО[2,1-a]ИЗОХИНОЛИН-2-ОЛА И СВЯЗАННЫЕ С НИМИ СПОСОБЫ | |
| AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| NO20025641D0 (no) | Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister | |
| PA8495101A1 (es) | Derivados de 13-metileritromicina | |
| AR066972A1 (es) | Derivados azapeptidicos | |
| EA201000101A1 (ru) | Производные пиримидина 934 | |
| PA8561501A1 (es) | Lactamas como antagonistas de taquiquininas | |
| PE20060937A1 (es) | Derivados de sulfonilbencimidazol como agonistas del receptor cannabinoide 2 (cb2) | |
| NO20025640D0 (no) | Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister | |
| AR039190A1 (es) | Derivados de benzofurano, composicion farmaceutica y medicamento que comprende el compuesto | |
| AR049274A1 (es) | Acido2-{[2-(2-metilaminopirimidin-4-il)-1h-indol-5-carbonil]amino}-3-(fenilpiridin-2-ilamino)propionico sustancialmente puro como inhibidor selectivo de la quinasa ikk-2 | |
| AR051795A1 (es) | Derivados de hidantoina inhibidores de metaloproteinasas | |
| CL2022000893A1 (es) | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |